Shared Value: Common Values for Your Health
Interview with Dr. Christian Woergetter, MES, Managing Director of Chiesi Pharmaceuticals GmbH
The development and manufacturing of medications in Europe pose a challenge in a global comparison. More and more companies are relocating their production to non-European countries. Chiesi Pharmaceuticals GmbH from Vienna, a pharmaceutical company focusing on respiratory and rare diseases, remains committed to sustainability and loyalty to its location despite all market challenges.
"As a family-owned company with headquarters in Italy, we have both our production and our research and development departments in Europe," explains Managing Director Dr. Christian Woergetter. "That's why we have not experienced any supply shortages. We operate in all areas according to high social standards. The care and empowerment of our patients is a central aspect of our philosophy and strategy. This also includes the availability of our products."
Guiding Principle: Sustainability
In addition, the well-being of employees and the protection of the planet are important cornerstones of the Shared Value concept of Chiesi Pharmaceuticals. By 2035, the company aims to achieve CO2 neutrality. "Environmentally friendly propellant is an important keyword for us," says Dr. Christian Woergetter. "We are intensively working on gases with a lower CO2 footprint and are investing 350 million EUR for this purpose. We hope to be able to bring to the European market by 2029 inhalation sprays for asthma and COPD that cause lower CO2 emissions."
Sustainability and business success are not mutually exclusive for Chiesi Pharmaceuticals, but rather condition each other. The company is B Corp certified and part of a global movement that stands for regenerative, inclusive, and fair economy. Thus, Chiesi Pharmaceuticals is committed to meeting high standards.
Market-Leading Products
Therapies for respiratory diseases are the mainstay of Chiesi Pharmaceuticals. The company is a leading player in COPD and asthma with metered dose inhalers and dry powder inhalers. In the field of rare diseases, therapies for genetically determined diseases such as Alpha-1 Antitrypsin Deficiency, Cystic Fibrosis, or Fabry disease are among the flagships of the portfolio. Specialty products for hospitals in the areas of transplantation medicine, neonatology, and critical care complete the range.
Thinking as a Community
"We have been through challenging times, and personally, it is especially important to me that we all learn to act more solidarily and think as a community," says Dr. Christian Woergetter. "In the long term, we want to be stable and successful in the market, but also be perceived as a sustainable company for the greatest possible benefit of our patients and responsibility towards the community and the environment."